Molecule and method for activating dendritic cells and application thereof

By constructing a TNF-α-GM-CSF fusion protein, the problem of the influence of cytokine half-life differences on dendritic cell activation was solved, achieving efficient activation and proliferation of DC cells and improving the efficacy of tumor treatment.

CN118909139APending Publication Date: 2024-11-08广东壹加再生医学研究院有限公司
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410995826.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing technologies, the two cytokines TNF-α and GM-CSF have significantly different half-lives, which affects the activation of dendritic cells and makes it difficult for them to work synergistically and efficiently.

Method used

A TNF-α-GM-CSF fusion protein was constructed, and the TNF-α gene and GM-CSF gene were linked by PCR overlap extension. The protein was cloned into the pBV220 vector and expressed in host bacteria to stimulate immature dendritic cells. Under optimized culture conditions, the protein was promoted to mature and activate the cells.

Benefits of technology

The TNF-α-GM-CSF fusion protein promotes the activation and proliferation of DC cells, enhances their phagocytic activity, expresses CD80, CD86 and CD83 molecular markers at high levels, and secretes IL-12 at high levels, thus fully activating autologous T cells and enhancing the anti-tumor therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909139A_ABST
    Figure CN118909139A_ABST
Patent Text Reader

Abstract

The invention provides a molecule and a method for activating dendritic cells and application of the molecule and the method, and belongs to the field of cell biology. According to the invention, a serum-free culture solution containing GM-CSF and IL-4 is used for culturing immature dendritic cells, and TNF-alpha-GM-CSF fusion protein is used for stimulating the immature dendritic cells to obtain activated dendritic cells. The TNF-alpha-GM-CSF fusion protein overcomes the defect that the activation effect is affected due to large half-life difference of TNF-alpha and GM-CSF, brings a new effect, can promote activation and proliferation of DC cells, can promote phagocytic activity of the DC cells, enables the DC cells to express CD80, CD86 and CD83 surface molecular markers at a high level, can secrete IL-12 at a high level, and has a good application prospect. The dendritic cells are fully mature and the autologous T cells are efficiently activated, so that the tumor treatment effect is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of cell biology, and in particular relates to a molecule, method and application of activating dendritic cells. Background Art

[0002] Dendritic cells (DC) are the main antigen presenting cells (APCs). They can directly activate initial T cells to induce adaptive immune responses. They are important mediators of innate and adaptive immune responses, and play an important role in inducing immune tolerance, maintaining body homeostasis, and anti-tumor immune responses. DC precursor cells enter the peripheral blood from the bone marrow and are distributed to various tissues of the body to become immature DCs (iDCs). Antigens or danger signals activate iDCs through receptor or non-receptor mediated mechanisms. After activation, iDCs can recruit macrophages, neutrophils, natural killer cells, and immature lymphocytes to the site of inflammation. Then, iDCs migrate to lymphatic organs through lymphatic vessels to search for antigen-specific T cells, and transform into mature DCs (mDCs) through different specific signal transduction processes.

[0003] Cytokines act as messengers between immune cells and are critical for coordinating immune responses. GM-CSF has multiple immunomodulatory activities, including promoting the differentiation of granulocytes, macrophages, and eosinophils, and activating and recruiting dendritic cells (DCs). GM-CSF stimulates monocytes / macrophages to produce TNF-α. TNF-α is a cytokine with multiple biological activities that plays an important role in anti-tumor immunity. TNF-α usually acts as a stimulatory molecule to stimulate the maturation of DCs. TNF-α and GM-CSF can work synergistically to promote the differentiation and maturation of DCs, and the activated DCs activate autologous T cells to further achieve anti-tumor effects. However, the half-life of TNF-α and GM-CSF is very different, which often makes their synergistic effects difficult to predict. Therefore, there is an urgent need to find new methods to activate dendritic cells to overcome the influence of large differences in cytokine half-life on the activation effect. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a molecule, method and application of activating dendritic cells to solve the problem that the large difference in the half-life of cytokines affects the activation effect of dendritic cells.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a molecule for activating dendritic cells, wherein the molecule is a TNF-α-GM-CSF fusion protein;

[0007] The method for constructing the TNF-α-GM-CSF fusion protein is as follows: TNF-α gene and GM-CSF gene are connected by PCR overlap extension technique to obtain TNF-α-GM-CSF fusion gene, TNF-α-GM-CSF fusion gene is cloned into pBV220 vector, and host bacteria are transformed to express to obtain TNF-α-GM-CSF fusion protein.

[0008] The present invention also provides a method for activating dendritic cells, which uses the molecules for activating dendritic cells to stimulate immature dendritic cells.

[0009] Preferably, the stimulation time is 24 to 48 hours.

[0010] Preferably, the immature dendritic cells are peripheral blood mononuclear cells.

[0011] Preferably, the peripheral blood mononuclear cells are cultured in a serum-free culture medium containing GM-CSF and IL-4.

[0012] Preferably, the content of GM-CSF in the serum-free culture medium is 10-20 ng / mL, and the content of IL-4 is 5-15 ng / mL.

[0013] Preferably, the immature dendritic cells are cultured with serum-free culture medium and then cultured with one or more of polypeptide antigens, tumor cell lysates, recombinant vectors carrying antigen coding sequences, or RNA encoding antigens.

[0014] The present invention also provides the use of dendritic cells activated by the method in preparing DC vaccines or anti-tumor drugs.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The TNF-α-GM-CSF fusion protein of the present invention overcomes the defect that the activation effect of the two cytokines TNF-α and GM-CSF is affected by the large difference in half-life, and brings new effects, which can promote the activation and proliferation of DC cells, promote the phagocytic activity of DC cells, make them express CD80, CD86 and CD83 surface molecular markers at high levels, and can secrete IL-12 at high levels, so that dendritic cells fully mature and efficiently activate autologous T cells, thereby improving the tumor treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a graph showing the results of flow cytometry detection of the phagocytic activity of DC2.4 cells;

[0018] Figure 2 This is a graph showing the results of detecting the proliferation activity of DC2.4 cells using the cell counting method;

[0019] Figure 3 This is the result of ELISA testing the secretion content of cytokine IL-10;

[0020] Figure 4 This is the result of ELISA testing the secretion content of cytokine IL-12;

[0021] Figure 5 This is the result of ELISA testing the secretion content of cytokine IFN-γ;

[0022] Figure 6 This is the result of flow cytometry detection of dendritic cell immune molecule phenotype CD80 fluorescence intensity;

[0023] Figure 7 This is the result of flow cytometry detection of dendritic cell immune molecule phenotype CD83 fluorescence intensity;

[0024] Figure 8 This is the result of flow cytometry detection of dendritic cell immune molecule phenotype CD86 fluorescence intensity;

[0025] Fig. 9 This is a graph showing the results of flow cytometry detection of the MHC-II fluorescence intensity of dendritic cell immune molecule phenotype. DETAILED DESCRIPTION

[0026] The present invention provides a molecule for activating dendritic cells, wherein the molecule is a TNF-α-GM-CSF fusion protein;

[0027] The method for constructing the TNF-α-GM-CSF fusion protein is as follows: TNF-α gene and GM-CSF gene are connected by PCR overlap extension technique to obtain TNF-α-GM-CSF fusion gene, TNF-α-GM-CSF fusion gene is cloned into pBV220 vector, and host bacteria are transformed to express to obtain TNF-α-GM-CSF fusion protein.

[0028] The present invention also provides a method for activating dendritic cells, which uses the molecules for activating dendritic cells to stimulate immature dendritic cells.

[0029] In the present invention, the immature dendritic cells are peripheral blood mononuclear cells; the peripheral blood mononuclear cells are cultured with a serum-free culture medium containing GM-CSF and IL-4; the content of GM-CSF in the serum-free culture medium is preferably 10-20 ng / mL, more preferably 12-18 ng / mL, and the content of IL-4 is preferably 5-15 ng / mL, more preferably 7-12 ng / mL; the culture conditions are preferably cultured in a 30-40°C, 3-8% CO2 incubator for 5-7 days, more preferably cultured in a 32-39°C, 4-7% CO2 incubator for 6 days; after culturing with serum-free culture medium, polypeptide antigens, The immature dendritic cells are cultivated with one or more of tumor cell lysate, a recombinant vector carrying an antigen coding sequence, or RNA encoding an antigen; then the immature dendritic cells are stimulated with the molecule for activating dendritic cells to obtain activated dendritic cells; the molecule for activating dendritic cells is a TNF-α-GM-CSF fusion protein; the TNF-α-GM-CSF fusion protein is constructed by: connecting the TNF-α gene and the GM-CSF gene by PCR overlap extension to obtain the TNF-α-GM-CSF fusion gene, connecting the TNF-α-GM-CSF fusion gene and the pBV220 vector by double enzyme digestion and T4 DNA ligase, and then transforming them into Escherichia coli for expression to obtain the TNF-α-GM-CSF fusion protein; the stimulation time is preferably 24 to 48 hours, and more preferably 26 to 44 hours.

[0030] The present invention also provides the use of dendritic cells activated by the method in preparing DC vaccines or anti-tumor drugs.

[0031] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0032] The TNF-α-GM-CSF fusion protein was constructed by connecting the TNF-α gene and the GM-CSF gene by PCR overlap extension to obtain the TNF-α-GM-CSF fusion gene, cloning the TNF-α-GM-CSF fusion gene into the pBV220 vector, and transforming it into a host bacterium for expression to obtain the TNF-α-GM-CSF fusion protein. The fusion protein was constructed and synthesized by Jiangsu Rongtai Biotechnology Co., Ltd., and the activity assay showed that the TNF-α activity concentration contained in the fusion protein was 9.6×10 6 U / mg, GM-CSF activity concentration is 1.5×10 7 U / mg.

[0033] AIM-V serum-free medium was purchased from Thermo Fisher Scientific (China) Co., Ltd.;

[0034] CEA protein antigen was purchased from Nanjing Okai Biotechnology Co., Ltd.;

[0035] Cytokines TNF-α and GM-CSF were purchased from Peprotech;

[0036] DC2.4 cells were purchased from Wuhan Sean Biotechnology Co., Ltd.;

[0037] RPMI 1640-10% FCS complete medium was purchased from Shanghai Yuchun Biotechnology Co., Ltd.;

[0038] Flow cytometer was purchased from CaliburFACS, BD;

[0039] ELISA kits were purchased from ebioscience, catalog numbers 88-7126-88, 88-7106-88;

[0040] Anti-CD80 and MHC-II fluorescent-labeled antibodies were purchased from Thermo Fisher Scientific (China) Co., Ltd.;

[0041] Anti-CD83, CD86 fluorescently labeled antibodies Shanghai Boyan Biotechnology Co., Ltd.

[0042] Example 1

[0043] Peripheral blood mononuclear cells were suspended and cultured in AIM-V serum-free medium containing 15 ng / mL GM-CSF and 10 ng / mL IL-4. After culturing in a 37°C, 5% CO2 incubator for 6 days, CEA protein antigen loading was added for 24 hours. TNF-α-GM-CSF fusion protein was added, and mature dendritic cells were harvested after further culturing in a 37°C, 5% CO2 incubator for 36 hours.

[0044] Example 2

[0045] Peripheral blood mononuclear cells were suspended and cultured in AIM-V serum-free medium containing 10 ng / mL GM-CSF and 5 ng / mL IL-4. After culturing in a 37°C, 5% CO2 incubator for 5 days, CEA protein antigen loading was added for 24 hours. TNF-α-GM-CSF fusion protein was added, and mature dendritic cells were harvested after further culturing in a 37°C, 5% CO2 incubator for 24 hours.

[0046] Example 3

[0047] Peripheral blood mononuclear cells were suspended and cultured in AIM-V serum-free medium containing 20 ng / mL GM-CSF and 15 ng / mL IL-4. After culturing in a 37°C, 5% CO2 incubator for 7 days, CEA protein antigen loading was added for 24 hours. TNF-α-GM-CSF fusion protein was added, and mature dendritic cells were harvested after continued culture in a 37°C, 5% CO2 incubator for 48 hours.

[0048] Experimental Example 1

[0049] Effects of TNF-α-GM-CSF on the phagocytosis and proliferation of DC cells

[0050] Preparation of tumor cell conditioned medium (TCM): Mouse melanoma B16F10 cells were cultured to the logarithmic growth phase, digested with trypsin, and cultured at 1×10 6 Cells / mL RPMI 1640-10% FCS complete medium (abbreviated as R10) were inoculated into 6-well plates, and the supernatant was collected after overnight culture, and centrifuged at 2000 r / min for 5 min to remove cell debris, which was the tumor cell conditioned medium (TCM).

[0051] Mouse immature DC cell line DC2.4 was cultured to the logarithmic growth phase and then digested with trypsin and centrifuged at 5×10 5 Cells / mL R10 were inoculated into 6-well plates, and 1 mL TCM was added to each well, and 2000 U of TNF-α-GM-CSF fusion protein (calculated as TNF-α activity), cytokine TNF-α, GM-CSF or TNF-α+GM-CSF combination were added. R10 medium culture without TCM was used as the blank control for routine culture, and TCM culture without cytokines was used as the negative control.

[0052] 1. TNF-α-GM-CSF promotes DC2.4 cell phagocytosis

[0053] DC2.4 cells cultured under TCM conditions were trypsinized and 2×10 5 The cells were resuspended in 100 μL phosphate buffered saline (PBS), FD40 solution was added to a final concentration of 1 mg / mL, and incubated at 37°C for 15 min. After washing with PBS three times, the mean fluorescence intensity (MFI) was measured by flow cytometry.

[0054] Experimental results: Figure 1As shown. The phagocytic activity of cells in the TCM environment was significantly lower than that in the conventional culture environment, indicating that TCM treatment can inhibit the phagocytic activity of DC2.4 cells. TNF-α-GM-CSF can significantly promote the phagocytic activity of DC2.4 cells in both conventional culture environments and TCM environments, and the effect is much higher than TNF-α, GM-CSF or the combination of GM-CSF and TNF-α.

[0055] 2.TNF-α-GM-CSF promotes the proliferation of DC2.4 cells

[0056] DC2.4 cells cultured in TCM conditions were trypsinized for 24 h and counted.

[0057] Experimental results: Figure 2 As shown. Compared with conventional culture conditions, cell proliferation was significantly inhibited under TCM culture conditions. Both GM-CSF and TNF-α had a certain reversal effect, but could not completely reverse it. Unlike the effect of a single cytokine, TNF-α-GM-CSF could significantly promote cell proliferation under TCM conditions.

[0058] Experimental Example 2

[0059] Effects of TNF-α-GM-CSF on the levels of cytokines (IL-10, IL-12 and IFN-γ) secreted by DC cells

[0060] The supernatant of dendritic cells activated in Example 1 and the supernatant of dendritic cells cultured without adding TNF-α-GM-CSF (control group) were collected, and ELISA detection was performed using an ELISA kit to detect the secretion of IL-10, IL-12 and IFN-γ in the supernatant.

[0061] Experimental results: Figures 3 to 5 As shown in the figure, the expression levels of IL-10, IL-12 and IFN-γ under TNF-α-GM-CSF treatment were much higher than those in the control group, indicating that TNF-α-GM-CSF can significantly promote the activation of dendritic cells.

[0062] Experimental Example 3

[0063] The dendritic cells activated in Example 1 and the dendritic cells obtained by culturing without adding TNF-α-GM-CSF (control group) were collected, washed with PBS and resuspended to adjust the cell concentration to 1×10 6 / mL, take 100μL and add it to the centrifuge tube, then add fluorescent labeled antibodies (anti-CD80, CD83, CD86 and MHC-II) respectively, react at 4℃, avoid light for 15min, wash twice with flow cytometry buffer, detect on the machine, and analyze with flowjov10 software. Flow cytometry was used to detect the comparison of dendritic cell immune molecular phenotype CD80, CD83, CD86 and MHC-II fluorescence intensity.

[0064] Experimental results: Figures 6 to 9 The expression of CD80, CD83, CD86 and MHC-II in the TNF-α-GM-CSF stimulation group was higher than that in the control group, indicating that the mature dendritic cells provided by the present invention have stronger ability to present immune molecule antigens on the surface and stronger ability to activate T cells.

[0065] Experimental Example 4

[0066] CCK-8 assay to detect the effect of activated dendritic cells on T cell proliferation

[0067] The dendritic cells activated in Example 1 and the dendritic cells cultured without adding TNF-α-GM-CSF (control group) were co-cultured with T cells (derived from the same source as peripheral blood mononuclear cells) at a cell number ratio of 1:10 for 5 days, and the proliferation of T cells was detected by CCK method.

[0068] Experimental results: as shown in Table 1.

[0069] Table 1 Comparison of the effects of Example 1 and the control group on T cell proliferation response

[0070] Grouping T cell proliferation rate (%, x±s) Example 1 301.54±38.16 Control group 145.06±43.28

[0071] As can be seen from Table 1, the dendritic cells activated by TNF-α-GM-CSF of the present invention can promote and increase the proliferation rate of T cells and enhance the immune response ability.

[0072] It can be seen from the above embodiments and experimental examples that the TNF-α-GM-CSF fusion protein of the present invention can promote the activation and proliferation of DC cells, can promote the phagocytic activity of DC cells, make them express CD80, CD86 and CD83 surface molecular markers at high levels, and can secrete IL-12 at high levels, so that dendritic cells fully mature and efficiently activate autologous T cells, thereby improving the tumor treatment effect.

[0073] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A molecule for activating dendritic cells, characterized in that The molecule is a TNF-α-GM-CSF fusion protein; The method for constructing the TNF-α-GM-CSF fusion protein is as follows: TNF-α gene and GM-CSF gene are connected by PCR overlap extension technique to obtain TNF-α-GM-CSF fusion gene, TNF-α-GM-CSF fusion gene is cloned into pBV220 vector, and host bacteria are transformed to express to obtain TNF-α-GM-CSF fusion protein.

2. A method for activating dendritic cells, characterized in that: Stimulate immature dendritic cells using the dendritic cell activating molecule according to claim 1.

3. The method according to claim 2, characterized in that The stimulation time is 24 to 48 hours.

4. The method according to claim 2, characterized in that: The immature dendritic cells are peripheral blood mononuclear cells.

5. The method according to claim 4, characterized in that The peripheral blood mononuclear cells are cultured in a serum-free culture medium containing GM-CSF and IL-4.

6. The method according to claim 5, characterized in that The content of GM-CSF in the serum-free culture medium is 10-20 ng / mL, and the content of IL-4 is 5-15 ng / mL.

7. The method according to claim 5, characterized in that After being cultured in serum-free culture medium, the immature dendritic cells are cultured with one or more of polypeptide antigens, tumor cell lysates, recombinant vectors carrying antigen coding sequences, or RNA encoding antigens.

8. Use of dendritic cells activated by the method according to any one of claims 3 to 7 in the preparation of DC vaccines or anti-tumor drugs.

Citation Information

Patent Citations

  • Prostatic cancer therapeutic vaccine modified on surface of GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) / TNF (Tumor Necrosis Factor)-alpha membrane

    CN101863984A

  • Multiple cytokine-antibody complexes

    CN1382158A

  • Long-acting granulocyte macrophage-colony stimulating factor

    WO2023196747A1